📊 BLLN Key Takeaways
Is BillionToOne, Inc. (BLLN) a Good Investment?
BillionToOne demonstrates exceptional operational momentum with 100% revenue growth and accelerating profitability (155% net income growth), coupled with a fortress balance sheet (76% cash-to-assets, 0.18x debt/equity). However, concerning capital efficiency metrics (3.6% ROE, 2.6% ROA) and a meaningful gap between operating cash flow ($15.4M) and net income ($18M) warrant closer monitoring of cash deployment strategy and earnings quality.
BillionToOne shows unusually strong top-line momentum, with revenue doubling year over year while remaining profitable and free-cash-flow positive. The balance sheet is a major strength, with nearly $496M in cash, low leverage, and very high liquidity, which gives the company flexibility to fund growth. The main fundamental constraint is that profitability is still relatively thin, so the durability of margin expansion matters more than raw revenue growth.
BillionToOne, Inc. Key Strengths (BLLN)
- Exceptional growth trajectory: 100% YoY revenue growth with net income growing 155% YoY, demonstrating strong market execution and operational leverage
- Superior profitability: 73% gross margin, 16.5% operating margin, and 16.6% net margin indicate strong pricing power and operational efficiency in medical laboratory services
- Conservative capital structure: 0.18x debt/equity ratio, $537.5M cash position (76% of assets), and strong liquidity (10.92x current ratio) provide strategic flexibility and downside protection
- Revenue growth is exceptionally strong at 100.0% year over year, indicating meaningful commercial traction
- Gross margin of 68.3% supports an attractive underlying business model with room for operating leverage
- Balance sheet is very strong, with substantial cash, low debt-to-equity of 0.12x, and current ratio of 11.69x
BLLN Stock Risks: BillionToOne, Inc. Investment Risks
- Severely depressed returns despite profitability: ROE of 3.6% and ROA of 2.6% suggest capital inefficiency or excess equity; $537.5M cash hoard indicates suboptimal capital deployment
- Earnings quality concern: Operating cash flow ($15.4M) lags net income ($18M) by 15%, raising questions about working capital management and non-cash charges inflating reported profits
- Growth sustainability risk: 100% YoY revenue growth may not be maintainable at scale; deceleration could expose underlying operational or competitive challenges
- Net margin of 2.4% and operating margin of 5.3% remain modest, leaving limited room for execution missteps
- Returns on capital are still low, with ROE at 1.6% and ROA at 1.2%, suggesting profits have not yet scaled efficiently
- Growth quality needs continued monitoring to ensure recent profitability and free cash flow are sustainable rather than temporary
Key Metrics to Watch
- Operating cash flow trend relative to net income - validate cash generation quality and working capital efficiency
- Return on equity trajectory - should improve significantly as excess capital is productively deployed
- Revenue growth rate modulation - monitor for deceleration signaling market saturation or competitive pressure
- Cash deployment strategy and capital allocation efficiency - critical to understanding utilization of $537.5M balance sheet
- Operating margin and net margin progression
- Operating cash flow and free cash flow consistency
BillionToOne, Inc. (BLLN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.92x current ratio provides a solid financial cushion.
BLLN Profit Margin, ROE & Profitability Analysis
BLLN vs Healthcare Sector: How BillionToOne, Inc. Compares
How BillionToOne, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is BillionToOne, Inc. Stock Overvalued? BLLN Valuation Analysis 2026
Based on fundamental analysis, BillionToOne, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
BillionToOne, Inc. Balance Sheet: BLLN Debt, Cash & Liquidity
BLLN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: BillionToOne, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-8.45 indicates the company is currently unprofitable.
BLLN Revenue Growth, EPS Growth & YoY Performance
BLLN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $59.0M | -$4.0M | $0.34 |
| Q3 2025 | $38.4M | $1.5M | $0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BillionToOne, Inc. Dividends, Buybacks & Capital Allocation
BLLN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for BillionToOne, Inc. (CIK: 0002070849)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BLLN
What is the AI rating for BLLN?
BillionToOne, Inc. (BLLN) has a Combined AI Grade of A from Claude (A) and ChatGPT (A) with 79% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BLLN's key strengths?
Claude: Exceptional growth trajectory: 100% YoY revenue growth with net income growing 155% YoY, demonstrating strong market execution and operational leverage. Superior profitability: 73% gross margin, 16.5% operating margin, and 16.6% net margin indicate strong pricing power and operational efficiency in medical laboratory services. ChatGPT: Revenue growth is exceptionally strong at 100.0% year over year, indicating meaningful commercial traction. Gross margin of 68.3% supports an attractive underlying business model with room for operating leverage.
What are the risks of investing in BLLN?
Claude: Severely depressed returns despite profitability: ROE of 3.6% and ROA of 2.6% suggest capital inefficiency or excess equity; $537.5M cash hoard indicates suboptimal capital deployment. Earnings quality concern: Operating cash flow ($15.4M) lags net income ($18M) by 15%, raising questions about working capital management and non-cash charges inflating reported profits. ChatGPT: Net margin of 2.4% and operating margin of 5.3% remain modest, leaving limited room for execution missteps. Returns on capital are still low, with ROE at 1.6% and ROA at 1.2%, suggesting profits have not yet scaled efficiently.
What is BLLN's revenue and growth?
BillionToOne, Inc. reported revenue of $108.4M.
Does BLLN pay dividends?
BillionToOne, Inc. does not currently pay dividends.
Where can I find BLLN SEC filings?
Official SEC filings for BillionToOne, Inc. (CIK: 0002070849) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BLLN's EPS?
BillionToOne, Inc. has a diluted EPS of $0.34.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is BLLN's fundamental grade?
Based on our AI fundamental analysis in June 2026, BillionToOne, Inc. has a A grade with 79% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is BLLN stock overvalued or undervalued?
Valuation metrics for BLLN: ROE of 3.6% (sector avg: 15%), net margin of 16.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is BLLN's AI grade for 2026?
Our dual AI analysis gives BillionToOne, Inc. a combined A grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is BLLN's free cash flow?
BillionToOne, Inc.'s operating cash flow is $15.4M, with capital expenditures of $4.5M. FCF margin is 10.1%.
How does BLLN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 16.6% (avg: 12%), ROE 3.6% (avg: 15%), current ratio 10.92 (avg: 2).